Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Top Cited Papers
- 1 September 2014
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (25), 2794-2803
- https://doi.org/10.1200/jco.2013.54.1870
Abstract
Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human epidermal growth factor receptor 2–enriched, basal-like, luminal A, and luminal B subtypes. Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and chemotherapy. Although luminal cancers share similarities, the studies conducted in recent years using next-generation sequencing technology show that luminal A and B breast cancers should be perceived as distinct entities, with specific oncogenic drivers, rather than more proliferative varieties of luminal tumors. This review discusses the definition and molecular characterization of luminal B breast cancer and presents the available clinical evidence for chemotherapy and endocrine therapy patterns of response. It also provides an overview of ongoing research on molecularly targeted agents for this disease.This publication has 115 references indexed in Scilit:
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled AnalysisJournal of Clinical Oncology, 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epitheliumEMBO Molecular Medicine, 2011
- ZNF703 gene amplification at 8p12 specifies luminal B breast cancerEMBO Molecular Medicine, 2011
- Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy responseBreast Cancer Research and Treatment, 2009
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancerBreast Cancer Research and Treatment, 2009
- Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifenBreast Cancer Research and Treatment, 2008
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006